Application of radioactive iodine-125 microparticles in hepatocellular carcinoma with portal vein embolus  

作　　者：Peng Meng Ji-Peng Ma Xiao-Fei Huang Kang-Le Zhang 

机构地区：[1]The Fourth Department of Oncology,Yantai Hospital of Traditional Chinese Medicine,Yantai 264001,Shandong Province,China [2]Department of Medical Services,Yantai Hospital of Traditional Chinese Medicine,Yantai 264001,Shandong Province,China [3]Department of Hepatobiliary Surgery,The First Affiliated Hospital of Sun Yatsen University,Guangzhou 510062,Guangdong Province,China [4]The Third Department of Oncology,Yantai Hospital of Traditional Chinese Medicine,Yantai 264001,Shandong Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2024年第7期2023-2030,共8页世界胃肠外科杂志（英文版）（电子版）

摘　　要：BACKGROUND Radioactive iodine-125(125I)microparticle therapy is a new type of internal radiation therapy that has shown unique advantages in the treatment of malignant tumors,especially hepatocellular carcinoma.Patients with hepatocellular carcinoma frequently experience portal vein embolism,which exacerbates the difficulty and complexity of treatment.125I particles,used in local radiotherapy,can directly act on tumor tissue and reduce damage to surrounding healthy tissue.Through retrospective analysis,this study discussed the efficacy and safety of radioactive 125I particles in portal vein embolization patients with hepatocellular carcinoma in order to provide more powerful evidence supporting clinical treatment.AIM To investigate the effect of transcatheter arterial chemoembolization combined with portal vein 125I particle implantation in the treatment of primary liver cancer patients with portal vein tumor thrombus and its influence on liver function.METHODS The clinical data of 96 patients with primary liver cancer combined with portal vein tumor thrombus admitted to our hospital between January 2020 and December 2023 were retrospectively analyzed.Fifty-two patients received treatment with transcatheter arterial chemoembolization and implantation of 125I particles in the portal vein(combination group),while 44 patients received treatment with transcatheter arterial chemoembolization alone(control group).The therapeutic effects on tumor lesions,primary liver cancer,and portal vein tumor embolisms were compared between the two groups.Changes in relevant laboratory indexes before and after treatment were evaluated.The t test was used to compare the measurement data between the two groups,and the χ^(2) test was used to compare the counting data between groups.RESULTS The tumor lesion response rate in the combination group(59.62%vs 38.64%)and the response rate of patients with primary liver cancer complicated with portal vein tumor thrombus(80.77%vs 59.09%)were significantly greater than those in the control grou

关 键 词：Radioactive iodine-125 Hepatocellular carcinoma Transcatheter arterial chemoembolization Portal vein embolus Retrospective study 

分 类 号：R735.7[医药卫生—肿瘤]